MedPath

Clinical Efficacy Study of Tolvaptan on Patients with Autosomal Dominant Polycystic Kidney Disease

Phase 4
Conditions
Autosomal Dominant Polycystic Kidney Disease
Registration Number
JPRN-UMIN000015715
Lead Sponsor
Kyorin University School of Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
100
Inclusion Criteria

Not provided

Exclusion Criteria

1)Patients who did not or will not give consent to participate to the study protocol. 2)Patients who is considered to be excluded by physicians.

Study & Design

Study Type
Interventional,observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Annual change rate of Total Kidney Volume (TKV slope; ml/year, % /year)
Secondary Outcome Measures
NameTimeMethod
Annual change rate of eGFR (eGFR slope; ml/min/1.73m2 per year) which is estimated by creatinine and cystatin-C.
© Copyright 2025. All Rights Reserved by MedPath